Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity

Cited by (1,000)

Items 701–800 of 1,000

1. Combing the Cancer Genome for Novel Kinase Drivers and New Therapeutic Targets
   Pedro Torres‐Ayuso, John Brognard · 2019 · Cancers
2. Identification of Intrinsic Drug Resistance and Its Biomarkers in High-Throughput Pharmacogenomic and CRISPR Screens
   Iñigo Ayestaran, Ana Galhoz, Elmar Spiegel, Ben S. Sidders, Jonathan R. Dry, Frank Dondelinger, Andreas Bender, Ultan McDermott, Francesco Iorio, Michael P. Menden · 2020 · Patterns
3. Epigenetic Therapy as a Potential Approach for Targeting Oxidative Stress–Induced Non-Small-Cell Lung Cancer
   Ridhima Wadhwa, Keshav Raj Paudel, Shakti Dhar Shukla, Madhur D. Shastri, Gaurav Gupta, Hari Prasad Devkota, Dinesh Kumar Chellappan, Philip M. Hansbro, Kamal Dua · 2021 · Springer eBooks
4. Can structural features of kinase receptors provide clues on selectivity and inhibition? A molecular modeling study
   S. Ravichandran, Brian T. Luke, Jack Collins · 2015 · Journal of Molecular Graphics and Modelling
5. Navigating into the binding pockets of the HER family protein kinases: discovery of novel EGFR inhibitor as antitumor agent
   Cai Li, Wei Liu, Jin-Feng Ning, Wei-Qing Meng, Jing Hu, Yanbin Zhao, Chao Liu · 2015 · Drug Design Development and Therapy
6. Bioluminescent kinase strips: A novel approach to targeted and flexible kinase inhibitor profiling
   Jacquelyn Hennek, J. Alves, Eric Yao, Said A. Goueli, Hicham Zegzouti · 2015 · Analytical Biochemistry
7. HER-2-directed, small-molecule antagonists.
   Michelle R. Arkin, Mark M. Moasser · 2008 · PubMed
8. Tyrosine kinase activating mutations in human malignancies: Implications for diagnostic pathology
   Joseph A. Holden, Carlynn Willmore‐Payne, Lester James Layfield · 2008 · Experimental and Molecular Pathology
9. An extraction from Trametes robiniophila Murr. (Huaier) inhibits non-small cell lung cancer proliferation via targeting to epidermal growth factor receptor
   Fei Lv, Xiaoqi Li, Ying Wang · 2022 · Bioengineered
10. Designing, molecular docking, and dynamics simulations studies of 1,2,3-triazole clamped Uracil-Coumarin hybrids against EGFR tyrosine kinase
    Mohit Sanduja, Jyoti Gupta, Ravi Rawat, Uttam Singh, Saurabh Manaswita Verma · 2020 · Journal of Applied Pharmaceutical Science
11. DFT, molecular docking and molecular dynamics simulation studies on some recent natural products revealing their EGFR tyrosine kinase inhibition potential
    Taner Erdoğan, Fatma Oğuz Erdoğan · 2023 · Journal of Biomolecular Structure and Dynamics
12. Integrative bioinformatic analysis to identify potential phytochemical candidates for glioblastoma
    Hafiza Maria Usmani Rana, Haseeb Nisar, Jignesh Prajapati, Dweipayan Goswami, Ravi Rawat, Volkan Eyüpoğlu, Samiah Shahid, Anum Javaid, Wardah Nisar · 2024 · Heliyon
13. New thiazolidin-4-ones as anti-cervical cancer agents targeting EGFR: design, synthesis, and computational studies
    Wafa AbuBaker Bawazir, Nesreen Said I. Ahmed, Somaia S. Abd El‐Karim, Ahmed Fikry El-Sayed, Manal M. Anwar · 2024 · Future Medicinal Chemistry
14. EGFR and CYP signaling disruption underlies 6PPD-quinone hepatotoxicity: Insights from a network and machine learning approach
    Wenjie Zhang, Banghua Wu, Chengbin Hu, Weifeng Rong, Yongshun Huang, Shijie Hu, Yiru Qin · 2025 · Toxicology
15. Mechanisms of resistance to reversible inhibitors of EGFR tyrosine kinase in non-small cell lung cancer
    Paweł Adam Krawczyk, Radosław Mlak, Tomasz Powrózek, Marcin Nicoś, Dariusz Mirosław Kowalski, Kamila Wojas‐Krawczyk, Janusz Milanowski · 2012 · Współczesna Onkologia
16. From Biology to Therapy: Improvements of Therapeutic Options in Lung Cancer
    Luigi Formisano, Valerie Malyvanh Jansen, Roberta Marciano, Roberto Bianco · 2018 · Anti-Cancer Agents in Medicinal Chemistry
17. Allosteric therapies for lung cancer
    Ling Ye, Meiling Jing, Xiangdong Wang · 2015 · Cancer and Metastasis Reviews
18. Mechanistic insights into differential requirement of receptor dimerization for oncogenic activation of mutant EGFR and its clinical perspective
    Jeonghee Cho · 2020 · BMB Reports
19. Pathway‐extended gene expression signatures integrate novel biomarkers that improve predictions of patient responses to kinase inhibitors
    Ashis J. Bagchee‐Clark, Eliseos J. Mucaki, Tyson Whitehead, Peter K. Rogan · 2020 · MedComm
20. A survey of the kinome pharmacopeia reveals multiple scaffolds and targets for the development of novel anthelmintics
    Jessica J. Knox, Nicolas Joly, Edmond M. Linossi, José A. Carmona‐Negrón, Natalia Jura, Lionel Pintard, William J. Zuercher, Peter John Roy · 2021 · Scientific Reports
21. Emerging Role of EGFR Mutations in Creating an Immune Suppressive Tumour Microenvironment
    Simran S. Kapoor, Dietmar M. W. Zaiss · 2021 · Biomedicines
22. Hybrid Pharmacophore- and Structure-Based Virtual Screening Pipeline to Identify Novel EGFR Inhibitors That Suppress Non-Small Cell Lung Cancer Cell Growth
    Chia-Wei Weng, Chi-Hsuan Wei, Jeng-Yuan Tsai, Yi‐Hua Lai, Gee‐Chen Chang, Jeremy J.W. Chen · 2022 · International Journal of Molecular Sciences
23. Correlation of EGFR mutation subtypes and survival in surgically treated brain metastasis from non-small-cell lung cancer
    Pang-Shuo Perng, Hui‐Ping Hsu, Po‐Hsuan Lee, Chi-Chen Huang, Chien‐Chung Lin, Jung‐Shun Lee · 2022 · Asian Journal of Surgery
24. The effect of EGFR‐TKIs on survival in advanced non‐small‐cell lung cancer with EGFR mutations: A real‐world study
    Xiaoqing Yu, Jinfei Si, Jingwen Wei, Yanling Wang, Yan Ping Sun, Jia'nan Jin, Xiaoyan Zhang, Tonghui Ma, Zhengbo Song · 2022 · Cancer Medicine
25. Design, synthesis and biological evaluation of novel 3,4-dihydro-2H-[1,4]oxazino [2,3-f]quinazolin derivatives as EGFR-TKIs
    Xuemei Qin, Peng Liu, Yihai Li, Liming Hu, Ye-Xin Liao, Tingting Cao, Lifang Yang · 2022 · Bioorganic & Medicinal Chemistry Letters
26. Targeting of SOS1: from SOS1 Activators to Proteolysis Targeting Chimeras
    Gerhard Hamilton, Sandra Stickler, Barbara Rath · 2023 · Current Pharmaceutical Design
27. Evaluation of the Potential Therapeutic Properties of Liquidambar orientalis Oil
    Mehmet Cengiz Baloğlu, Lütfiye Yıldız Özer, Buket Pirci, Gökhan Zengin, Abdullahi İbrahim Uba, Yasemin Çelik Altunoğlu · 2023 · Chemistry & Biodiversity
28. Metal complexes bearing EGFR‐inhibiting ligands as promising anticancer agents
    Xiaoyan Ma, Zhaoran Wang, Yifei Li, Yawen Wang, Wukun Liu · 2024 · Medicinal Research Reviews
29. JAK3 inhibitor VI is a mutant specific inhibitor for epidermal growth factor receptor with the gatekeeper mutation T790M
    Naoyuki Nishiya · 2015 · World Journal of Biological Chemistry
30. Systematic molecular profiling of inhibitor response to the clinical missense mutations of ErbB family kinases in human gastric cancer
    Xi Ding, Tong Cheng, Rong Chen, Xi Wang, Dongyun Gao, Lixia Zhu · 2019 · Journal of Molecular Graphics and Modelling
31. Design, synthesis, and biological evaluation of hydroxamic acid-substituted 2,4-diaryl aminopyrimidines as potent EGFRT790M/L858R inhibitors for the treatment of NSCLC
    Lixue Chen, Yunhao Zhang, Changyuan Wang, Zeyao Tang, Qiang Meng, Hunjun Sun, Yan Qi, Xiaodong Ma, Lei Li, Yanxia Li et al. · 2021 · Bioorganic Chemistry
32. Elevating CDCA3 Levels Enhances Tyrosine Kinase Inhibitor Sensitivity in TKI-Resistant EGFR Mutant Non-Small-Cell Lung Cancer
    Katherine B. Sahin, Esha T. Shah, Genevieve P. Ferguson, Christopher Molloy, Priyakshi Kalita‐de Croft, Sarah A. Hayes, Amanda L. Hudson, Emily K. Colvin, Hannah Kamitakahara, Rozelle M. Harvie et al. · 2021 · Cancers
33. EGFR genomic alterations in cancer: prognostic and predictive values
    Giuseppe Bronte · 2009 · Frontiers in Bioscience-Elite
34. Structure‐Based Pharmacophore Modeling from Multicomplex: a Comprehensive Pharmacophore Generation of Protein Kinase CK2 and Virtual Screening Based on it for Novel Inhibitors
    Hao‐Peng Sun, Jia Liang. Zhu, Feihong Chen, Qidong You · 2011 · Molecular Informatics
35. Towards a Truly General Intermolecular Binding Affinity Calculator for Drug Discovery & Design
    Wei Li, Gary Vottevor · 2023 · Preprints.org
36. Inhibiting Two Cellular Mutant Epidermal Growth Factor Receptor Tyrosine Kinases By Addressing Computationally Assessed Crystal Ligand Pockets
    Jia-Hau Lee, Wei‐Chen Lin, Tsung‐Kai Wen, Chihuei Wang, Ying‐Ting Lin · 2019 · Future Medicinal Chemistry
37. Design, Synthesis and Cytotoxic Studies of Novel 4-anilinoquinazoline Derivatives of Potential Agents for Non-small-cell Lung Cancer
    Deepak Dwivedi, Ram Kishore Agrawal, Sanyog Jain, Kaushik Kuche · 2023 · Letters in Drug Design & Discovery
38. Synthesis, cytotoxicity and antioxidant activity of new conjugates of N-acetyl-d-glucosamine with α-aminophosphonates
    Leysan R. Khabibulina, B. F. Garifullin, Ravil F. Aznagulov, Olga V. Andreeva, I. Yu. Strobykina, Mayya G. Belenok, Alexandra D. Voloshina, Dinara F. Abramova, Alexandra Borisovna Vyshtakalyuk, Anna Pavlovna Lyubina et al. · 2024 · Carbohydrate Research
39. Elucidating the potential of EGFR mutated NSCLC and identifying its multitargeted inhibitors
    Anakha D. Rajeeve, Ramasamy Yamuna, P. K. Krishnan Namboori · 2025 · Scientific Reports
40. Epidermal growth factor receptor mutation in combination with expression of MIG6 alters gefitinib sensitivity
    Yoshimi Naruo, Takeshi Nagashima, Ryoko Ushikoshi‐Nakayama, Yuko Saeki, Takashi Nakakuki, Takashi Naka, Hiroshi Tanaka, Shih‐Feng Tsai, Mariko Okada · 2011 · BMC Systems Biology
41. In silico evaluation of the resistance of the T790M variant of epidermal growth factor receptor kinase to cancer drug Erlotinib
    Inderpal Singh, Shashank Kumar Singh, Vijeshwar Verma, Vladimir Nikolaevich Uversky, Ratna Chandra · 2017 · Journal of Biomolecular Structure and Dynamics
42. In-silico Studies of the Antiproliferative Activity of New Anilinoquinazoline Derivatives Against NSCLC Cells
    Muhammad Kumayl Abdulwahab, Ke Han Tan, Rashidi Dzul Keflee, Kok Hoong Leong, Choon Han Heh, Azhar Ariffin · 2020 · Journal of Molecular Structure
43. Screening of phytochemicals from Clerodendrum inerme (L.) Gaertn as potential anti-breast cancer compounds targeting EGFR: an in-silico approach
    Nusrath Yasmeen, Anis Ahmad Chaudhary, Ravi Ranjan Kumar Niraj, Sudarshan Singh Lakhawat, Pushpender Kumar Sharma, Vikram Kumar · 2023 · Journal of Biomolecular Structure and Dynamics
44. Design, synthesis and characterization of “clickable” 4-anilinoquinazolinekinase inhibitors
    B. Gayani K. Perera, Dustin J. Maly · 2008 · Molecular BioSystems
45. QSAR of clinically important EGFR mutant L858R/T790M pyridinylimidazole inhibitors
    Shehnaz Fatima, Divyani Pal, Subhash Mohan Agarwal · 2019 · Chemical Biology & Drug Design
46. Orthosteric and allosteric modulation of human kinases A mechanistic view
    Puniti Mathur · 2020 · Frontiers in bioscience
47. Late recurrence of lung adenocarcinoma harboring EGFR exon 20 insertion (A763_Y764insFQEA) mutation successfully treated with osimertinib
    Kei Kunimasa, Kazumi Nishino, Yoji Kukita, Shingo Matsumoto, Hayato Kawachi, Takahisa Kawamura, Takako Inoue, Motohiro Tamiya, Keiichiro Honma, Naotoshi Sugimoto et al. · 2021 · Cancer Genetics
48. In silico Evaluation of Selected Compounds from Bergenia ciliata (Haw.) Sternb against Molecular Targets of Breast Cancer
    Sabiha Enam Spriha, S. M. Abdur Rahman · 2022 · Indian Journal of Pharmaceutical Education and Research
49. Mapping inhibitor response to the in-frame deletions, insertions and duplications of epidermal growth factor receptor (EGFR) in non-small cell lung cancer
    Jingheng Ning, Qi Wu, Zhenguo Liu, Jianhui Wang, Xianfu Lin · 2015 · Journal of Receptors and Signal Transduction
50. Investigating mutation-specific biological activities of small molecules using quantitative structure-activity relationship for epidermal growth factor receptor in cancer
    P. Anoosha, Ramasamy Sakthivel, M. Michael Gromiha · 2017 · Mutation research. Fundamental and molecular mechanisms of mutagenesis
51. EGFR degraders in non‐small‐cell lung cancer: Breakthrough and unresolved issue
    Jiayi Shen, Liping Chen, Jihu Liu, Anzhi Li, Lüyin Zheng, Sheng Chen, Yongdong Li · 2024 · Chemical Biology & Drug Design
52. Design, synthesis, and biological evaluation of novel amidoxime or amidine analogues of some 4-anilino-6,7-dimethoxyquinazolines with a potent EGFR inhibitory effect
    Cemre Acar, Hakan Göker, Özgür Kütük, İsmail Çeli̇k, Tunca Gul Altuntas · 2025 · Bioorganic Chemistry
53. Identification and characterization of Bufalin as a novel EGFR degrader
    Yidi Tai, Lulu Kong, Yan Wang, Dongyu Zhao, Xu Chen, Qingnan Wu, Hao Jia, Xi Wang, Xingyang Liu, Dongshao Chen et al. · 2025 · Cancer Letters
54. Lung Cancer Genomics in the Era of Accelerated Targeted Drug Development
    Priyanga Wijesinghe, Aliccia B. Bollig-Fischer · 2015 · Advances in experimental medicine and biology
55. Addressing epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small cell lung cancer
    Shoko Noda, Shintaro Kanda · 2016 · Expert Review of Respiratory Medicine
56. Autophosphorylation of the carboxyl‐terminal domain is not required for oncogenic transformation by lung‐cancer derived EGFR mutants
    Jeonghee Cho, Sujin Kim, Jinyan Du, Matthew M. Meyerson · 2018 · International Journal of Cancer
57. Major Clinical Response to Afatinib Monotherapy in Lung Adenocarcinoma Harboring EGFR Exon 20 Insertion Mutation
    László Urbán, Róbert Dóczi, Barbara Vodicska, Dóra Tihanyi, Magdolna Horváth, Dóra Kormos, István Takács, Zsolt Pápai-Székely, Zsuzsanna Póka-Farkas, Edit Várkondi et al. · 2020 · Clinical Lung Cancer
58. Molecular analysis and systematic profiling of allosteric inhibitor response to clinically significant epidermal growth factor receptor missense mutations in non‐small cell lung cancer
    Yan Zhao, Dan Zhu, Junzhen Gao · 2021 · Journal of the Chinese Chemical Society
59. MicroRNA‑27b‑3p inhibits the proliferation and invasion of cutaneous squamous cell carcinoma by targeting EGFR and MMP‑13
    Daning Liang, Zhen‐Ning Zhang · 2021 · Oncology Letters
60. Probing altered enzyme activity in the biochemical characterization of cancer
    Mowaffaq Adam Ahmed Adam, Christal Dyane Sohl · 2022 · Bioscience Reports
61. Allosteric activation of preformed EGF receptor dimers by a single ligand binding event
    Endang R. Purba, Ei‐ichiro Saita, Reetesh Raj Akhouri, Lars‐Göran Öfverstedt, Gunnar Wilken, Ulf Skoglund, ICHIRO N. MARUYAMA · 2022 · Frontiers in Endocrinology
62. Metal organic framework supported surface modification of synthesized nickel/nickel oxide nanoparticles via controlled PEGylation for cytotoxicity profile against MCF-7 breast cancer cell lines via docking analysis
    Gulam Abbas · 2023 · Journal of Molecular Structure
63. Nuclear export signal mutation of epidermal growth factor receptor enhances malignant phenotypes of cancer cells.
    Lei Nie, Ying‐Nai Wang, Jung-Mao Hsu, Junwei Hou, Yu‐Yi Chu, Li-Chuan Chan, Longfei Huo, Yongkun Wei, Rong Deng, Jun Tang et al. · 2023 · PubMed Central
64. Class act: safety comparison of approved tyrosine kinase inhibitors for non-small-cell lung carcinoma
    Mauricio Burotto, Syed Abbas Ali, Geraldine O’Sullivan Coyne · 2014 · Expert Opinion on Drug Safety
65. Using Novel Descriptor Accounting for Ligand–Receptor Interactions To Define and Visually Explore Biologically Relevant Chemical Space
    Obdulia Rabal, Julen Oyarzábal · 2012 · Journal of Chemical Information and Modeling
66. Comparison of the characteristics of uncommon epidermal growth factor receptor (EGFR) mutations and EGFR‑tyrosine kinase inhibitor treatment in patients with non‑small cell lung cancer from different ethnic groups
    Qiao Zhang, Yanyan Cui, Jian Zhang, Jiayideng Kenjiabieke, Patiguli Aerxiding · 2020 · Experimental and Therapeutic Medicine
67. Discovery of Rhodanine and Thiazolidinediones as Novel Scaffolds for EGFR Inhibition: Design, Synthesis, Analysis and CoMSIA Studies
    Tisa Francis, Sheshagiri R. Dixit, B. R. Prashantha Kumar · 2020 · Polycyclic aromatic compounds
68. Resistor: An algorithm for predicting resistance mutations via Pareto optimization over multistate protein design and mutational signatures
    Nathan Guerin, Andreas Feichtner, Eduard Stefan, Teresa Kaserer, Bruce Randall Donald · 2022 · Cell Systems
69. Prediction of anti-EGFR drug resistance base on binding free energy and hydrogen bond analysis
    Weiqiang Zhou, Debby D. Wang, Hong Yan, Maria Pik Wong, Victor Ho-Fun Lee · 2013 · IEEE Conference on Computational Intelligence in Bioinformatics and Computational Biology (CIBCB)
70. Discovery of novel dual inhibitors of receptor tyrosine kinases EGFR and IGF-1R
    Cornelius Hempel, Frank Totzke, Christoph Schächtele, Abdulkarim Najjar, Wolfgang Sippl, Christoph Alexander Ritter, Andreas Hilgeroth · 2017 · Journal of Enzyme Inhibition and Medicinal Chemistry
71. Conformational Plasticity in Tyrosine Kinase Inhibitor–Kinase Interactions Revealed with Fluorescence Spectroscopy and Theoretical Calculations
    Muhammad Khattab, Feng Wang, Andrew H. A. Clayton · 2018 · The Journal of Physical Chemistry B
72. Gefitinib provides similar effectiveness and improved safety than erlotinib for advanced non-small cell lung cancer
    Wenxiong Zhang, Yiping Wei, Dongliang Yu, Jianjun Xu, Jinhua Peng · 2018 · Medicine
73. Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
    Mahlet Z. Tamirat, Kari J. Kurppa, Klaus Elenius, Mark S. Johnson · 2020 · Journal of Visualized Experiments
74. HR-LCMS based phytochemical analysis and anticancer activity of Triumfetta rhomboidea with molecular docking approach
    Nutan Kendre, Mohini Anandrao Salunke, Balaji Sopanrao Wakure, Pravin S. Wakte · 2024 · Journal of Applied Pharmaceutical Science
75. Synthesis of Para‐Acetylated Functionalized Ni(II)‐POCOP Pincer Complexes and Their Cytotoxicity Evaluation Against Human Cancer Cell Lines
    Arturo Sánchez‐Mora, Edwin Briñez-Ortega, Alejandro Pico, Lucero González‐Sebastián, Jesús Antonio Cruz-Navarro, Antonino Arenaza‐Corona, Nicolás Puentes‐Díaz, Jorge Alí‐Torres, Viviana Reyes‐Márquez, David Morales‐Morales · 2024 · Chemistry & Biodiversity
76. Biochemical analysis of EGFR exon20 insertion variants insASV and insSVD and their inhibitor sensitivity
    Hanchen Zhao, Tyler S. Beyett, Jie Jiang, Jaimin K. Rana, Ilse K. Schaeffner, Jhasmer Santana, Pasi Antero Janne, Michael J. Eck · 2024 · Proceedings of the National Academy of Sciences
77. Design and synthesis of s-triazine-Isatin hybrids with potent anticancer activity, targeting A549 lung adenocarcinoma via EGF inhibition
    Hessa H. Al‐Rasheed, Sarah A. AL-khamis, Assem Barakat, Aliaa A. Masoud, Ahmed A. Sobhy, Doaa Ahmad Ghareeb, Beatriz G. de la Torre, Fernando Alberício, Ayman El‐Faham · 2024 · Tetrahedron
78. Predicting Resistance to Small Molecule Kinase Inhibitors
    Anu Nagarajan, Katherine Amberg-Johnson, Evan Paull, Kunling Huang, Phani Ghanakota, Asela Chandrasinghe, Jackson Chief Elk, Jared M. Sampson, Lingle Wang, Robert Abel et al. · 2025 · Journal of Chemical Information and Modeling
79. STX-721, a Covalent EGFR/HER2 Exon 20 Inhibitor, Utilizes Exon 20–Mutant Dynamic Protein States and Achieves Unique Mutant Selectivity Across Human Cancer Models
    Raymond A. Pagliarini, Jack A. Henderson, Benjamin C. Milgram, Deanna R. Borrelli, Natasja Brooijmans, Brendan J. Hilbert, Michael R. Huff, Takahiro Ito, Gregory V. Kryukov, Brendon Ladd et al. · 2025 · Clinical Cancer Research
80. Synthesis of Caffeic Acid Amides Bearing 2,3,4,5-Tetra-hydrobenzo[b][1,4]dioxocine Moieties and Their Biological Evaluation as Antitumor Agents
    Jiwen Yuan, Han‐Yue Qiu, Pengfei Wang, Jigar A. Makawana, Yong-An Yang, Fei Zhang, Yong Yin, Jie Lin, Zhong‐Chang Wang, Hai‐Liang Zhu · 2014 · Molecules
81. EGFRisopred: a machine learning-based classification model for identifying isoform-specific inhibitors against EGFR and HER2
    Ravi Prakash Saini, Subhash Mohan Agarwal · 2021 · Molecular Diversity
82. Structure-based molecular networking, molecular docking, dynamics simulation and pharmacokinetic studies of Olax subscorpioidea for identification of potential inhibitors against selected cancer targets
    Akolade R. Oladipupo, Chinwe S. Alaribe, Adeniyi Sunday Ogunlaja, Mehdi A. Beniddir, Allen T. Gordon, Celina O. Ogah, Joy Okpuzor, Herbert A.B. Coker · 2023 · Journal of Biomolecular Structure and Dynamics
83. Structural elements that enable specificity for mutant EGFR kinase domains with next-generation small-molecule inhibitors
    Tahereh Damghani, Florian Wittlinger, Tyler S. Beyett, Michael J. Eck, Stefan Laufer, David E. Heppner · 2023 · Methods in enzymology on CD-ROM/Methods in enzymology
84. The next generation of EGFR inhibitors: a patenting perspective of PROTACs based EGFR degraders
    Pengyun Li, Bingkun Li, Ning Yang, Tingting Xu, Zhibing Zheng · 2023 · Expert Opinion on Therapeutic Patents
85. POTENTIAL COMPOUND DERIVED FROM CATHARANTHUS ROSEUS TO INHIBIT NON SMALL CELL LUNG CANCER (NSCLC)
    Poomalai Senthilraja, John Kayitare, Gowdham Manivel, S. Manikandaprabhu, Anand Krishnamurthy · 2015 · International Journal of Research in Ayurveda and Pharmacy
86. In Vitro Enzyme Kinetics Analysis of EGFR
    Zhihong Wang, Christine Candelora · 2016 · Methods in molecular biology
87. RBAK is upregulated in non‑small cell lung cancer and promotes cell migration and invasion
    Bingjun He, Bin Wang, Haiyong Wang, Chu Zhang, Yuanlin Wu, Linhai Fu, Guangmao Yu · 2019 · Experimental and Therapeutic Medicine
88. Inter-lobe Motions Allosterically Regulate the Structure and Function of EGFR Kinase
    Kei Moritsugu, Yoshihiko Nishino, Akinori Kidera · 2020 · Journal of Molecular Biology
89. Rational design of EGFR dimerization-disrupting peptides: A new strategy to combat drug resistance in targeted lung cancer therapy
    Qiuhong Liu, Jinqiao Zhou, Jing Gao, Wentao Ma, Shilei Wang, Xing Lihua · 2020 · Biochimie
90. Predicting potential residues associated with lung cancer using deep neural network
    Medha Pandey, M. Michael Gromiha · 2020 · Mutation research. Fundamental and molecular mechanisms of mutagenesis
91. Investigation of molecular mechanism leading to gefitinib and osimertinib resistance against EGFR tyrosine kinase: molecular dynamics and binding free energy calculation
    Amit Kant Singh, Abha Mishra · 2022 · Journal of Biomolecular Structure and Dynamics
92. Natural Phytocompounds from Common Indian Spices for Identification of Three Potential Inhibitors of Breast Cancer: A Molecular Modelling Approach
    Samik Hazra, Anindya Sundar Ray, Chowdhury Habibur Rahaman · 2022 · Molecules
93. Structure-Guided Strategies of Targeted Therapies for Patients with EGFR-Mutant Non–Small Cell Lung Cancer
    Zhenfang Du, Jinghan Sun, Yunkai Zhang, Nigaerayi Hesilaiti, Qi Xia, Heqing Cui, Na Fan, Xiaofang Xu · 2023 · Biomolecules
94. Computational Study of Bis-(1-(Benzoyl)-3-Methyl Thiourea) Platinum (II) Complex Derivatives as Anticancer Candidates
    Ruswanto Ruswanto, Richa Mardianingrum, Tita Nofianti, Resti Fizriani, Siswandono Siswandono · 2023 · Advances and Applications in Bioinformatics and Chemistry
95. The Learning and Evolution of Medicinal Chemistry against Kinase Targets
    Martin E. Swarbrick · 2011 · Royal Society of Chemistry eBooks
96. Clinical Applications of Kinase Inhibitors in Solid Tumors
    William J. Pao, Nicolas Girard · 2010 · Elsevier eBooks
97. Biomass-involved synthesis of N-substituted benzofuro[2,3-d]pyrimidine-4-amines and biological evaluation as novel EGFR tyrosine kinase inhibitors
    Jianfei Sheng, Zhihong Liu, Ming Yan, Xue‐Jing Zhang, Dejian Wang, Jun Xu, Ensheng Zhang, Yong Zou · 2017 · Organic & Biomolecular Chemistry
98. An innovative kinome platform to accelerate small-molecule inhibitor discovery and optimization from hits to leads
    Charu Chaudhry, Andrew J. Tebben, John S. Tokarski, R. M. Borzilleri, William J. Pitts, Jonathan Lippy, Litao Zhang · 2021 · Drug Discovery Today
99. A Discussion of Molecular Biology Methods for Protein Engineering
    Alexander Zawaira, Anil Pooran, Samantha Barichievy, Denis Chopera · 2011 · Molecular Biotechnology
100. Coevolution-based computational approach to detect resistance mechanism of epidermal growth factor receptor
     Gyan Prakash Rai, Asheesh Shanker · 2023 · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research